Media requests should be directed to: 

Katy Riddick, Voices of Alzheimer’s Secretariat  

E-mail: kriddick@highlanterngroup.com 

Phone: +1 202 223 2027 

FOR IMMEDIATE RELEASE 

OUR MINDS. OUR LIVES. OUR CHOICES. 

Voices of Alzheimer's Applauds FDA Advisory Panel's Endorsement of Donanemab

 Advocacy Group Urges Swift Approval and Access to Life-Changing Treatment

Washington, DC, June 11, 2024 – Voices of Alzheimer's, a leading advocacy organization dedicated to supporting individuals and families affected by Alzheimer's disease, commends the recent unanimous decision by the FDA advisory panel to recommend the approval of donanemab, an experimental drug by Eli Lilly, for the treatment of early-stage Alzheimer's.

The panel's endorsement highlights the moderate yet important benefits of donanemab in slowing cognitive decline among patients in the early stages of the disease, outweighing potential risks from adverse reactions. As Alzheimer's continues to afflict more than six million Americans, the urgent need for effective treatments is more pressing than ever.

Jim Taylor, President and CEO of Voices of Alzheimer's, expressed strong support in the public session of the meeting, and for the panel's decision.  He emphasized the critical importance of immediate access to innovative treatments like donanemab.

"We are encouraged by the advisory panel's unanimous vote in favor of donanemab's approval," said Taylor. "This decision brings hope to millions of families impacted by Alzheimer's. With approximately 2,000 people moving from mild to moderate stages of the disease each day, the urgency to provide access to effective treatments cannot be overstated. For these individuals, time is of the essence, and every moment counts."

The clinical trials for donanemab demonstrated that nearly half of the participants who received the treatment maintained their cognitive levels after one year, compared to 29 percent of those on a placebo. This promising outcome underscores the potential of donanemab to make a meaningful difference in the lives of those battling early-stage Alzheimer's, as well as for their loved ones.

Voices of Alzheimer's is committed to advocating for the swift FDA approval of donanemab and ensuring that patients have timely access to all potentially life-changing treatments. The organization will continue to work closely with regulatory bodies, healthcare providers, and the broader community to support innovative research and treatments that address the urgent needs of those affected by Alzheimer's disease.

 About Voices of Alzheimer's  

Voices of Alzheimer's is a non-profit organization dedicated to advocating for the rights and well-being of people living with Alzheimer's disease. Our mission is to empower people living with or at risk of Alzheimer’s and other cognitive illnesses, united by urgency, to drive equitable access to innovation in treatment and care. We are guided and led by those affected by Alzheimer’s, but with a broad membership including those individuals in the generation at risk.  Our primary focus is to draw attention to the unmet medical needs of people with Alzheimer’s – especially to ensuring the FDA and CMS get meritorious products approved and into the hands of patients. 

Learn more on the Voices of Alzheimer’s website, and on social media through Facebook, Twitter, Instagram, and TikTok.   
  

VoicesOfAD.com